Teijin Pharma inks exclusive license deal with Novartis

6 March 2023
teijin-big

Japan’s Teijin Parma has entered into an exclusive global license agreement with Swiss pharma giant Novartis (NOVN: VX) to research, develop, manufacture and commercialize an investigational pre-clinical candidate for proteinuric kidney diseases.

The investigational small molecule candidate was discovered at the Teijin Institute for Bio-medical Research, Teijin’s drug development base in Tokyo. The candidate acts in a genetically validated pathway and is believed to impact the pathogenesis of multiple kidney diseases.

This deal comes about since Novartis made the decision to divest its clinical non-alcoholic steatohepatitis (NASH) assets as part of its new strategy focusing on five core therapeutic segments: cardiovascular, hematology, solid tumors, immunology and neuroscience. Novartis last month announced it was pulling out of a NASH collaboration with US biotech Pliant Therapeutics (Nasdaq: PLRX).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical